ESC2017

News

A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients.

News

With $81.3 million raised, Vogenx is the latest in a staggering summer of biotech IPOs. But the queue past this point looks thin.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.